J9153 Injection daunorubicin, cytarabine
Also known as: daunorubicin-cytarabine liposome, Vyxeos
Intravenous injection of daunorubicin citrate liposome (daunorubicin-cytarabine combination liposomal therapy).
In Plain Language
liposomal combination chemotherapy; acute leukemia treatment
Clinical Context
Used for therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes.
RVU Information
CPT J9153 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9153?
CPT J9153 (Injection daunorubicin, cytarabine) is a J Codes (Drugs) code. Intravenous injection of daunorubicin citrate liposome (daunorubicin-cytarabine combination liposomal therapy).
How is J9153 administered?
CPT J9153 is administered by a healthcare provider, typically via injection or infusion. Used for therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9153 used?
Used for therapy-related acute myeloid leukemia and acute myeloid leukemia with myelodysplasia-related changes.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.